ARCHIVES

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

This article is from The Cancer Letter archive.

Vol. 11 No. 42 | November 1, 1985

Download PDF Visit The Full Archive

Related Articles

Bill Pressures HCFA To Launch Project On Reimbursement for Cancer Trials

July 26, 1996

USC Opts for Its own IL-2 Protocol, Shuns NCI Trial

May 8, 1987

HHS: Gallo Committed Scientific Misconduct In AIDS Virus Discovery

January 8, 1993

SBRT Delivers Higher Overall Survival Rates Compared to Conventional Radiation Therapy

November 30, 2012

Study Finds Short Term Tests Predict Carcinogenicity

April 25, 1980

ASCO, Pathologists Publish Guideline On Improving Accuracy Of HER2 Testing

December 29, 2006